87.29
Dexcom Inc stock is traded at $87.29, with a volume of 2.66M.
It is up +1.11% in the last 24 hours and up +1.74% over the past month.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$86.33
Open:
$85.77
24h Volume:
2.66M
Relative Volume:
0.69
Market Cap:
$33.26B
Revenue:
$4.15B
Net Income/Loss:
$535.20M
P/E Ratio:
65.14
EPS:
1.34
Net Cash Flow:
$575.20M
1W Performance:
+9.33%
1M Performance:
+1.74%
6M Performance:
+12.24%
1Y Performance:
-23.01%
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DXCM
Dexcom Inc
|
87.29 | 33.26B | 4.15B | 535.20M | 575.20M | 1.34 |
![]()
ABT
Abbott Laboratories
|
136.01 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
107.41 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
395.63 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
78.21 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-16-25 | Initiated | Truist | Buy |
May-30-25 | Initiated | Goldman | Buy |
Apr-10-25 | Initiated | Mizuho | Outperform |
Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-30-24 | Initiated | Redburn Atlantic | Neutral |
Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Mar-29-23 | Initiated | UBS | Buy |
Jan-26-23 | Initiated | Wolfe Research | Outperform |
Oct-18-22 | Initiated | Barclays | Equal Weight |
Oct-12-22 | Initiated | Jefferies | Buy |
Jul-15-22 | Initiated | Bernstein | Outperform |
Mar-02-22 | Resumed | BofA Securities | Buy |
Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
Jul-21-21 | Resumed | Cowen | Outperform |
May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Overweight |
Jan-06-21 | Upgrade | UBS | Neutral → Buy |
Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
May-27-20 | Reiterated | Piper Sandler | Overweight |
May-14-20 | Initiated | Wells Fargo | Equal Weight |
Mar-05-20 | Initiated | Citigroup | Buy |
Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
Oct-23-19 | Initiated | Stifel | Buy |
Nov-28-18 | Initiated | UBS | Neutral |
Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
May-11-18 | Initiated | BofA/Merrill | Buy |
May-03-18 | Reiterated | Canaccord Genuity | Buy |
Apr-04-18 | Initiated | Goldman | Sell |
Apr-04-18 | Initiated | Guggenheim | Neutral |
Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Dexcom EVP Brown sells $41k in shares - Investing.com
Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault' - inkl
Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.
Dexcom Ireland announce golfer Liam Nolan as a brand ambassador - Galway Advertiser
Dexcom recalls more than 2 million CGM receivers for lack of audible alarm - MedTech Dive
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 - Dexcom
Breakthrough Study Reveals Doctors Choose CGM Over Medications as Future of Type 2 Diabetes Treatment - Stock Titan
Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks - FinancialContent
Dexcom Faces TM Suit Over 'Stelo' Glucose Monitor Product - Law360
Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating - MSN
DexCom’s SWOT analysis: CGM leader’s stock poised for growth amid challenges - Investing.com
DexCom's SWOT analysis: CGM leader's stock poised for growth amid challenges - Investing.com
Expert Outlook: DexCom Through The Eyes Of 8 Analysts - Nasdaq
DexCom Stock: Is DXCM Underperforming the Health Care Sector? - MSN
DexCom (DXCM) Receives 'Buy' Rating from Truist Securities with $102 Price Target | DXCM Stock News - GuruFocus
DexCom (DXCM) Gains Analysts' Favor Despite Past Challenges - GuruFocus
DexCom Stock: Is DXCM Underperforming The Health Care Sector? - Barchart.com
DexCom (DXCM) Receives Buy Rating Amid Promising Market Prospects | DXCM Stock News - GuruFocus
Truist Initiates DexCom at Buy With $102 Price Target - MarketScreener
DexCom Insiders Sell US$11m Of Stock, Possibly Signalling Caution - simplywall.st
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice
Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - marketscreener.com
Insulet Releases Omnipod 5 App for iPhone with Dexcom G7 CGM in U.S. - Medical Product Outsourcing
Diabetes partnerships abound ahead of ADA - BioWorld MedTech
Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - MarketScreener
Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire
DexCom, Inc. (DXCM) Stock Analysis: Analyst Consensus Points to 13.59% Potential Upside - DirectorsTalk Interviews
DexCom (NASDAQ:DXCM) Stock Rating Upgraded by Wall Street Zen - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
BGM and CGM Market is Set to Experience a Revolutionary Growth | Abbott Laboratories , Dexcom, Medtronic PLC - openPR.com
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Should You Be Excited About DexCom, Inc.'s (NASDAQ:DXCM) 24% Return On Equity? - simplywall.st
Goldman Sachs Initiates Coverage of DexCom (XTRA:DC4) with Buy Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of DexCom (BIT:1DXCM) with Buy Recommendation - Nasdaq
DexCom (NASDAQ:DXCM) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - Nasdaq
Forecasting The Future: 7 Analyst Projections For DexCom - Benzinga
DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Call Transcript - MSN
Jefferies Adjusts Price Target on DexCom to $110 From $105, Maintains Buy Rating - marketscreener.com
Goldman Sachs Initiates DexCom at Buy With $104 Price Target - marketscreener.com
DexCom (DXCM) Receives Positive Coverage with Growth Potential | - GuruFocus
DexCom (DXCM) Receives Positive Coverage with Growth Potential | DXCM Stock News - GuruFocus
Dexcom’s EVP Sadie Stern sells $526,318 in shares - Investing.com
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - The Globe and Mail
DexCom, Inc. (DXCM) Stock Analysis: 15.97% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com
DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dexcom Inc Stock (DXCM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
FOLETTA MARK G | Director |
Jun 16 '25 |
Sale |
83.13 |
2,750 |
228,605 |
56,621 |
Brown Michael Jon | EVP, Chief Legal Officer |
Jun 16 '25 |
Sale |
82.80 |
500 |
41,400 |
95,102 |
AUGUSTINOS NICHOLAS | Director |
Jun 16 '25 |
Sale |
82.80 |
3,672 |
304,042 |
33,411 |
AUGUSTINOS NICHOLAS | Director |
Jun 13 '25 |
Sale |
81.69 |
2,618 |
213,864 |
37,083 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):